These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

245 related articles for article (PubMed ID: 19345151)

  • 1. Clonal expansion of B-cells in human systemic lupus erythematosus: evidence from studies before and after therapeutic B-cell depletion.
    Sfikakis PP; Karali V; Lilakos K; Georgiou G; Panayiotidis P
    Clin Immunol; 2009 Jul; 132(1):19-31. PubMed ID: 19345151
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Rituximab improves peripheral B cell abnormalities in human systemic lupus erythematosus.
    Anolik JH; Barnard J; Cappione A; Pugh-Bernard AE; Felgar RE; Looney RJ; Sanz I
    Arthritis Rheum; 2004 Nov; 50(11):3580-90. PubMed ID: 15529346
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Longterm clinical and immunological effects of anti-CD20 treatment in patients with refractory systemic lupus erythematosus.
    Lindholm C; Börjesson-Asp K; Zendjanchi K; Sundqvist AC; Tarkowski A; Bokarewa M
    J Rheumatol; 2008 May; 35(5):826-33. PubMed ID: 18398943
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Delayed memory B cell recovery in peripheral blood and lymphoid tissue in systemic lupus erythematosus after B cell depletion therapy.
    Anolik JH; Barnard J; Owen T; Zheng B; Kemshetti S; Looney RJ; Sanz I
    Arthritis Rheum; 2007 Sep; 56(9):3044-56. PubMed ID: 17763423
    [TBL] [Abstract][Full Text] [Related]  

  • 5. B cell depletion as a novel treatment for systemic lupus erythematosus: a phase I/II dose-escalation trial of rituximab.
    Looney RJ; Anolik JH; Campbell D; Felgar RE; Young F; Arend LJ; Sloand JA; Rosenblatt J; Sanz I
    Arthritis Rheum; 2004 Aug; 50(8):2580-9. PubMed ID: 15334472
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Variability in the biological response to anti-CD20 B cell depletion in systemic lupus erythaematosus.
    Albert D; Dunham J; Khan S; Stansberry J; Kolasinski S; Tsai D; Pullman-Mooar S; Barnack F; Striebich C; Looney RJ; Prak ET; Kimberly R; Zhang Y; Eisenberg R
    Ann Rheum Dis; 2008 Dec; 67(12):1724-31. PubMed ID: 18250115
    [TBL] [Abstract][Full Text] [Related]  

  • 7. B cell depletion therapy in systemic lupus erythematosus: relationships among serum B lymphocyte stimulator levels, autoantibody profile and clinical response.
    Cambridge G; Isenberg DA; Edwards JC; Leandro MJ; Migone TS; Teodorescu M; Stohl W
    Ann Rheum Dis; 2008 Jul; 67(7):1011-6. PubMed ID: 17962238
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Comparable heavy and light chain pairings in normal and systemic lupus erythematosus IgG(+) B cells.
    de Wildt RM; Tomlinson IM; van Venrooij WJ; Winter G; Hoet RM
    Eur J Immunol; 2000 Jan; 30(1):254-61. PubMed ID: 10602048
    [TBL] [Abstract][Full Text] [Related]  

  • 9. B-cell depletion for autoimmune thrombocytopenia and autoimmune hemolytic anemia in pediatric systemic lupus erythematosus.
    Kumar S; Benseler SM; Kirby-Allen M; Silverman ED
    Pediatrics; 2009 Jan; 123(1):e159-63. PubMed ID: 19074962
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A longitudinal analysis of SLE patients treated with rituximab (anti-CD20): factors associated with B lymphocyte recovery.
    Sutter JA; Kwan-Morley J; Dunham J; Du YZ; Kamoun M; Albert D; Eisenberg RA; Luning Prak ET
    Clin Immunol; 2008 Mar; 126(3):282-90. PubMed ID: 18226586
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Treatment with rituximab affects both the cellular and the humoral arm of the immune system in patients with SLE.
    Vallerskog T; Gunnarsson I; Widhe M; Risselada A; Klareskog L; van Vollenhoven R; Malmström V; Trollmo C
    Clin Immunol; 2007 Jan; 122(1):62-74. PubMed ID: 17046329
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Long-term comparison of rituximab treatment for refractory systemic lupus erythematosus and vasculitis: Remission, relapse, and re-treatment.
    Smith KG; Jones RB; Burns SM; Jayne DR
    Arthritis Rheum; 2006 Sep; 54(9):2970-82. PubMed ID: 16947528
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Phenotypic changes of lymphocytes in patients with systemic lupus erythematosus who are in longterm remission after B cell depletion therapy with rituximab.
    Iwata S; Saito K; Tokunaga M; Yamaoka K; Nawata M; Yukawa S; Hanami K; Fukuyo S; Miyagawa I; Kubo S; Tanaka Y
    J Rheumatol; 2011 Apr; 38(4):633-41. PubMed ID: 21159836
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The V(lambda)-J(lambda) repertoire of patients with systemic lupus erythematosus manifests characteristics of the natural antibody repertoire.
    Lee J; Cho YJ; Lipsky PE
    Arthritis Rheum; 2004 Aug; 50(8):2604-14. PubMed ID: 15334475
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Regeneration of the immunoglobulin heavy-chain repertoire after transient B-cell depletion with an anti-CD20 antibody.
    Rouzière AS; Kneitz C; Palanichamy A; Dörner T; Tony HP
    Arthritis Res Ther; 2005; 7(4):R714-24. PubMed ID: 15987473
    [TBL] [Abstract][Full Text] [Related]  

  • 16. B lymphocyte depletion therapy in children with refractory systemic lupus erythematosus.
    Marks SD; Patey S; Brogan PA; Hasson N; Pilkington C; Woo P; Tullus K
    Arthritis Rheum; 2005 Oct; 52(10):3168-74. PubMed ID: 16200620
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Lack of deleterious somatic mutations in the CD95 gene of plasmablasts from systemic lupus erythematosus patients and autoantibody-producing cell lines.
    Kurth J; Perniok A; Schmitz R; Iking-Konert C; Chiorazzi N; Thompson KM; Winkler T; Rajewsky K; Küppers R
    Eur J Immunol; 2002 Dec; 32(12):3785-92. PubMed ID: 12516573
    [TBL] [Abstract][Full Text] [Related]  

  • 18. B cell depletion therapy for 19 patients with refractory systemic lupus erythematosus.
    Podolskaya A; Stadermann M; Pilkington C; Marks SD; Tullus K
    Arch Dis Child; 2008 May; 93(5):401-6. PubMed ID: 18039744
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The effect of anti-CD40 ligand antibody on B cells in human systemic lupus erythematosus.
    Huang W; Sinha J; Newman J; Reddy B; Budhai L; Furie R; Vaishnaw A; Davidson A
    Arthritis Rheum; 2002 Jun; 46(6):1554-62. PubMed ID: 12115186
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Anti-CD20 monoclonal antibody in rheumatoid arthritis and systemic lupus erythematosus.
    Goldblatt F; Isenberg DA
    Handb Exp Pharmacol; 2008; (181):163-81. PubMed ID: 18071946
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.